|
Inmune Bio Inc (NASDAQ: INMB) |
|
Inmune Bio Inc
INMB's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Inmune Bio Inc's sales fell
in IV. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2945
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -2.45 %
Inmune Bio Inc net loss increased from $-9 millions, to $-9 millions in IV. Quarter 2024,
• More on INMB's Growth
|
|
Inmune Bio Inc realized a net loss in trailing twelve months.
Inmune Bio Inc realized cash reduction of $ -0.75 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 11182.93.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.28.
• More on INMB's Valuation
|
|
|
|
|
Inmune Bio Inc realized net loss in trailing twelve months.
Inmune Bio Inc realized cash outflow of $ -0.75per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 11182.93.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.28.
Inmune Bio Inc Price to Book Ratio is at 4.88 lower than Industry Avg. of 21925.93. and higher than S&P 500 Avg. of 0.01
• More on INMB's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com